Navigation Links
Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkin's Lymphoma (NHL)
Date:9/11/2007

a first-line randomized phase II/III study of the CHOP-R versus CPOP-R in previously untreated aggressive NHL patients. The study is evaluating replacing doxorubicin in the standard CHOP-R combination regimen (cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab) with pixantrone as part of the CPOP-R regimen (cyclophosphamide, pixantrone, vincristine, prednisone and rituximab). The objective of the study is to demonstrate similar objective response rates to the standard doxorubicin-based therapy with significantly less severe cardiac toxicities and other doxorubicin-related toxicities on the CPOP-R arm of the study. A total of 280 patients are expected to be enrolled.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines. The main adverse events associated with pixantrone in clinical trials to date include myelosuppression and alopecia.

About NHL

According to the SEER CanQuest Database and the American Cancer Society, in 2005 the prevalence of indolent NHL in the U.S. was 282,025 with 24,490 newly diagnosed patients. The prevalence of aggressive NHL in the U.S. was 99,880 with 31,900 newly diagnosed patients.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology pro
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Protalix BioTherapeutics, Inc. Receives Approval from the FDA to Initiate a Phase III Clinical Trial of prGCD
3. Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting
4. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
5. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Trovagene, Inc. (NASDAQ:   TROV), ... results from two clinical studies will be presented at ... urine-based diagnostic test for the detection of high risk ... scheduled to take place in Seattle ... . Additionally, a new U.S. patent was issued earlier ...
(Date:8/20/2014)... Reportlinker.com announces that ... its catalogue: EMR 2014: The Market ... http://www.reportlinker.com/p0833392/EMR-2014-The-Market-for-Electronic-Medical-Records.html Kalorama has continuously examined ... for nearly a decade, and each year we ... report has become the industry standard, oft-quoted by ...
(Date:8/20/2014)... Glenmark Pharmaceuticals S.A. (GPSA), ... India (GPL), announces the discovery and initiation of ... candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR ... Biologics Research Centre located in La Chaux-de-Fonds, ... on Glenmark,s innovative BEAT antibody technology platform which ...
Breaking Medicine Technology:Trovagene Provides Update on Its Urine-Based HPV Test 2Trovagene Provides Update on Its Urine-Based HPV Test 3EMR 2014: The Market for Electronic Medical Records 2EMR 2014: The Market for Electronic Medical Records 3EMR 2014: The Market for Electronic Medical Records 4EMR 2014: The Market for Electronic Medical Records 5EMR 2014: The Market for Electronic Medical Records 6EMR 2014: The Market for Electronic Medical Records 7EMR 2014: The Market for Electronic Medical Records 8Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 2Glenmark Enters Oncology With the Discovery and Initiation of IND Enabling Studies of an Innovative Bispecific Antibody 3
(Date:8/20/2014)... August 20, 2014 The Workgroup ... nonprofit authority on the use of health IT ... the full agenda for its annual fall conference, ... Efficiency. WEDI-Con 2014 will take place at the ... 2014, attracting a diverse cross-section of payers, providers, ...
(Date:8/20/2014)... Doctors at the University of Hong Kong claim to ... mice by injecting them with a vaccine that changes their ... on its website. Click here to read the full ... Institute of Microbiology created a vaccine using a protein called ... the vaccine is designed to prevent mesothelioma cells from disabling ...
(Date:8/20/2014)... August 20, 2014 Today, Zane Benefits, ... on open enrollment for 2015. , According to Zane ... up in November, employees are encouraged to start thinking ... in 2015, the open enrollment period will run from ... enrollment 2015 individuals can purchase a new individual health ...
(Date:8/20/2014)... The report “Automotive Airbag and ... Global Analysis: by Geography - Trends and Forecasts ... defines automotive airbag and seatbelt market in terms ... growth opportunities in the coming years as well ... restrains, growth indicators, challenges, legislation trends, market dynamics, ...
(Date:8/20/2014)... In a recent article published by ... London (UCL) study showed that dental experts from around ... teeth was the most effective. Analysis of 66 different ... were frequently recommended, but none were favored by a ... experienced cosmetic dentist Dr. Patrick J. Broome, ...
Breaking Medicine News(10 mins):Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 2Health News:WEDI Releases Full Conference Agenda for Its Annual Fall Conference – WEDI-Con 2014 3Health News:New Research Study Finds Vaccine Stops Mesothelioma in Lab Mice, According to Surviving Mesothelioma Website 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3
... ... Interim Leadership division as senior vice president. A seasoned executive with nearly 20 years of ... , ... 2009 -- B. E. Smith recently hired Deirdre Byrne to lead the firm’s ...
... , MIAMI, Dec. 17 Physicians Healthcare ... today announced that it has issued its financial statements for ... being posted today on the Pink Sheets (www.pinksheets.com). ... , Physicians Healthcare Management Group, Inc. (Phyhealth) is a developer ...
... the employment and sociodemographic characteristics involved in the exposure of ... often work standing up or have to lift heavy objects, ... are frequently exposed to some physical risk in their place ... to exposure to workplace hazards", M Carmen Gonzlez, lead author ...
... PITTSBURGH, Dec. 17 Stem cells that could one day ... easily harvested from the tissue of the umbilical cord, just ... to treat some blood disorders, said University of Pittsburgh School ... the Journal of Biomedicine and Biotechnology . ...
... ... Online , ... Fla. (PRWEB) December 17, 2009 -- Open enrollment has begun for Villanova’s newly online ... schedules can’t accommodate a campus-based program. With the university’s Master of Science in Human ...
... 17 CareFusion Corporation (NYSE: CFN ) announced today ... TRC Capital Corporation (TRC) to purchase up to four million shares ... of common stock outstanding. TRC,s offer price of $23.50 per share ... stock on Dec. 14, 2009, the last full trading day prior ...
Cached Medicine News:Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 2Health News:Deirdre Byrne Joins B. E. Smith as Senior Vice President, Interim Leadership Services 3Health News:Phyhealth Issues September 30, 2009 Financial Statements 2Health News:Almost two-thirds of pregnant women believe they are regularly exposed to physical risk at work 2Health News:Umbilical cord could be new source of plentiful stem cells, say Pitt researchers 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 2Health News:A World-Class HR Master's Degree Is Now Within Reach – 100% Online 3Health News:CareFusion Recommends Rejection of Mini-Tender Offer by TRC Capital 2
The NOW Flu A test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results and tre...
... The Shandon Finesse ME+ is designed ... in todays busy laboratories by being one ... microtomes offered today. Excellent for routine wax ... Finesse ME + provides high quality sections ...
The Pach IV is the premier product for cornea thickness measurement in conjunction with Glaucoma screening....
The Shandon Linistat Linear Stainer is a compact answer to H&E frozen section protocols, with a footprint that fits on top of most cryostas to streamline workflow during frozen sectioning....
Medicine Products: